Pharma and Healthcare Insight

Pharma & Healthcare Insight brings you analysis of regional trends, regulatory changes, projects and investments plus competitive intelligence on the growth strategies of leading companies in the sector

See Prices or Subscribe

Key stories from this month's issue...

Industry Trend Analysis - Political Turmoil Brings Increasing Short-Term Uncertainties - AUG 2016

Americas July 2016 / Brazil / Industry

The impeachment of President Dilma Rousseff and the imminent Michel Temer presidency will keep political risk elevated over the coming quarters in Brazil, contributing to increasing uncertainty in terms of policy direction within the pharmaceutical and healthcare sector. Nonetheless, over a multiyear timeframe, the Brazilian electorate will demand progress on promised reforms, including higher-quality public services and greater government transparency. This will boost the long-term growth outlook for Brazil's pharmaceutical and healthcare sector. Regardless of who takes up the presidential role, government commitment to healthcare will continue to be supported.


Industry Trend Analysis - Healthcare Reforms To Shape Pharmaceutical Business Strategies - AUG 2016

Asia July 2016 / Asia / Industry

Reforms to healthcare financing will be a key theme within South East Asia (SEA). Owing to the varying levels of development among the markets, the specific focus of these changes will differ. While the primary concern for frontier markets will be to establish a foundation for universal healthcare, developed states will instead be focused on sustaining and expanding their medical systems. This will see a corresponding rise in government contributions to healthcare spending that will create a greater incentive to control medicine spending in SEA.


Industry Trend Analysis - Economic Strength And Healthcare Reform To Boost Opportunities - AUG 2016

Emerging Europe July 2016 / Poland / Industry

Poland will remain one of the most attractive pharmaceutical and healthcare markets in the CEE region. Strong economic growth will boost short-term increases in both healthcare expenditure and drug sales, while in the long term the introduction of a tax-funded healthcare system will support strong growth. Opportunities for innovative drugmakers will be significant, with an ageing population and increasing accessibility for advanced treatment.


Industry Trend Analysis - Healthcare Ambitions Lowered In Run-Up To World Cup - AUG 2016

Middle East & Africa July 2016 / Qatar / Industry

On the back of ongoing massive investments in infrastructure projects for the FIFA 2022 World Cup, health infrastructure projects in Qatar will become increasingly subject to lengthy construction delays. Over the long term, however, the Qatari government will remain committed to the delivery of healthcare in the country, supported by the state's 20-year blueprint for new health infrastructure projects - many of which include primary healthcare facilities. A moderate acceleration in economic expansion from 2017 will support continuous investments into Qatar's healthcare sector, providing greater opportunities for multinational drugmakers in the process.


Industry Trend Analysis - Generic Competition To Hurt AstraZeneca's 2016 Sales - AUG 2016

Western Europe July 2016 / United Kingdom / Industry

AstraZeneca's shareholders will keep a close eye on the company's late-stage R&D pipeline and newly launched USD1.1bn cost-cutting plan - assessing whether management's strategy has the strength to offset the revenue erosion caused by generic drugs. Nexium lost patent protection in the US in February 2015, and Crestor faces patent expiry in the US in 2016.